Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Gene-Modified Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia by Sichuan Kelun Biotech Biopharmaceutical for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Gene-Modified Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia is under clinical development by Sichuan Kelun...
Data Insights
Gene-Modified Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia by Sichuan Kelun Biotech Biopharmaceutical for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Gene-Modified Cell Therapy to Target CD33 for Relapsed and Refractory Acute Myeloid Leukemia is under clinical development by Sichuan Kelun...